A detailed history of New Edge Advisors, LLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 19,376 shares of COLL stock, worth $890,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,376
Previous 3,047 535.9%
Holding current value
$890,908
Previous $90,000 652.22%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$29.75 - $39.59 $485,787 - $646,465
16,329 Added 535.9%
19,376 $677,000
Q2 2025

Aug 14, 2025

BUY
$24.67 - $30.44 $56,592 - $69,829
2,294 Added 304.65%
3,047 $90,000
Q1 2025

May 15, 2025

BUY
$28.04 - $33.91 $21,114 - $25,534
753 New
753 $22,000
Q2 2023

Aug 14, 2023

SELL
$21.06 - $24.0 $1,705 - $1,944
-81 Reduced 37.33%
136 $2,000
Q1 2023

May 12, 2023

SELL
$23.0 - $29.88 $37,283 - $48,435
-1,621 Reduced 88.19%
217 $5,000
Q4 2022

Feb 14, 2023

BUY
$16.14 - $23.55 $29,665 - $43,284
1,838 New
1,838 $42,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.57B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.